Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 947-954

  Cozzolino, Mario ^a   Brancaccio, Diego ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chronic kidney disease; Paricalcitol; PTH; Vitamin D

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; DOXERCALCIFEROL; OXYGENASE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHORUS; TRANSFORMING GROWTH FACTOR ALPHA; VITAMIN D RECEPTOR;

CARDIOVASCULAR RISK; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DYSERYTHROPOIESIS; ENDOCRINE DISEASE; ENZYME ACTIVITY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; IMMUNE DEFICIENCY; KIDNEY FUNCTION; NONHUMAN; OSTEITIS FIBROSA; OSTEOMALACIA; PARATHYROID CELL; PARATHYROID HORMONE BLOOD LEVEL; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SOFT TISSUE CALCIFICATION; TISSUE DISTRIBUTION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE, CHRONIC; RECEPTORS, CALCITRIOL; RENAL DIALYSIS;

EID: 42649119148     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.947     Document Type: Review

References (58)

1. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997;52:3-9
2. Silver J, Bar Sela S, Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens 1997;6:321-6
3. Cozzolino M, Brancaccio D, Gallieni M, et al. Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 2005;18:5-8 Review on potential molecular mechanisms on vascular calcification in renal failure.
4. Denda M, Finch J, Slatopolsky E. Phosphorus accelerated the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996;28:596-602
5. Tominaga Y, Tsuzuki T, Uchida K, et al. Expression of Prad1/cyclin D1, retinoblastoma gene product, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999;55:1375-83
6. Reinhart TA, Ramberg CF, Horst RL. Comparison of receptor binding, biological activity and in vivo tracer kinetics for 1,25-dihydroxyvitamin D3 and, 1,25-dihydroxyvitamin D2, and its 24 epimer. Arch Biochem Biophys 1989;273:64-71
7. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997;96:1755-60
8. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992;19:303-17
9. Rodriguez M, Almaden Y, Hernandez A, Torres A. Effect of phosphate on the parathyroid gland: direct and indirect? Curr Opin Nephrol Hypertens 1996;5:321-8
10. Portale AA, Halloran BP, Morris RC Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989;83:1494-9
11. Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998;273:5253-9
12. Wang Q, Palnitkar S, Parfitt AM. Parathyroid cell proliferation in normal human parathyroid tissue: implications for the pathogenesis of hyperparathyroidism. Clin Endocrinol 1997;46:343-9
13. Cozzolino M, Lu Y, Finch J, et al. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001;60:2109-17
14. Cozzolino M, Lu Y, Sato T, et al. A critical role for enhanced-TGFα and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol 2005;289:1096-102
15. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord 2000:1:307-15
16. Ho C, Conner DA, Pollak MR, et al. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995;11:389-94
17. Li YC, Amling M, Pirro AE, et al. Normalization of mineral on homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998;139:4391-6
18. Kremer R, Bolivar I, Golztman D, Hendly GN. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989;125:935-41
19. Szabo A, Merke J, Beier E, et al. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989;35:1049-56
20. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 1990;86:1313-9
21. Tokumoto M, Tsuruya K, Fukuda K, et al. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia m patients with advanced secondary hyperparathyroidism. Kidney Int 2002;62:1196-207
22. Dusso A, Cozzolino M, Lu Y, et al. 1,25-Dihydroxyvitamin D downregulation of TGFα/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J Steroid Biochem Mol Biol 2004;89-90:507-11
23. Cordero JB, Cozzolino M, Lu Y, et al. 1,25-Dihydroxyvitamin D downregulates cell membrane growth-and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 2002;277:38965-71
24. Cogan MG, Covey CM, Arieff AI, et al. Central nervous system manifestations of hyperparathyroidism. Am J Med 1978;65:963-70
25. Mak RH, Bettinelli A, Turner C, et al. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab 1985;60:229-33
26. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002;17:2094-105
27. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephol 2001;12:2131-8
28. Cozzolino M, Dusso A, Slatopolsky E. Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001;12:2511-6
29. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003;14:S305-9
30. Blacher J, Safar ME, Guerin AP, et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003;63:1852-60
31. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-36
32. Jakoby MG 4th, Semenkovich CF. The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens 2000;9:11-5
33. Brancaccio D, Cozzolino M. The mechanism of calcium deposition in soft tissues. Contrib Nephrol 2005;149:279-86
34. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226-37
35. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40
36. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
37. Cozzolino M, Dusso AS, Liapis H, et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002;13:2299-308
38. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003;64:1653-61
39. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
40. Ishimura E, Nishizawa Y, Inaba M, et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in non dialyzed patients with chronic renal failure. Kidney Int 1999;55:1019-27
41. Messa P, Vallone C, Meoni G, et al. Direct in vivo assessment of parathyroid hormone calcium relationship curve in renal patients. Kidney Int 1994;46:1713-20
42. Papapoulos SE, Clemens TL, Fraher LJ, et al. Metabolites of vitamin D in human vitamin D deficiency. Effect of vitamin D or 1,25-dihydroxycolecalciferol. Lancet 1980;2:612-5
43. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):63-200
44. Massry SG, Coburn JW, Lee DB, et al. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 1973;78:357-64
45. Disthabanchong S, Hassan H, McConkey CL, et al. Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-101 osteoblast-like cells. Kidney Int 2004;65:897-903
46. Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of 'suppressed' parathyroid function. Kidney Int 1993;44:860-6
47. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21
48. Cournot-Witmer G, Zingraff J, Plachot JJ, et al. Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization. Kidney Int 1981;20:375-8
49. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38:45-50
50. Martin KJ, Gonzales E, Lindberg J, et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a vitamin D analogues for secondary hyperparathyroidism: a double-blind multicenter randomized trial. Am J Kidney Dis 2001;38:s57-63
51. Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001;56:315-23
52. Sprague SM, Llach F, Amdhal M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
53. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
54. Dobrez DG, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients. Nephrol Dial Transplant 2004;19:1174-81
55. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002;139:279-84
56. Finch J, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999;10:980-5
57. Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-6
58. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709-15